Immuneering (IMRX) Share-based Compensation (2020 - 2026)

Immuneering's Share-based Compensation history runs 7 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 3.29% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $6.3 million (down 6.9% YoY), while the FY2025 annual figure was $6.3 million, down 2.93% from the prior year.
• Share-based Compensation was $1.6 million for Q1 2026 at Immuneering, roughly flat from $1.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $1.7 million in Q4 2024 to a low of $897650.0 in Q1 2022.
• Historically, Share-based Compensation has averaged $1.4 million across 5 years, with a median of $1.5 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 392.61% in 2022, then retreated 11.22% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $1.0 million in 2022, then surged by 56.52% to $1.6 million in 2023, then increased by 5.13% to $1.7 million in 2024, then fell by 5.04% to $1.6 million in 2025, then decreased by 0.07% to $1.6 million in 2026.
• The last three Share-based Compensation figures came in at $1.6 million (Q1 2026), $1.6 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.